Quoin Pharmaceuticals Announces Publication of Peer-Reviewed Paper on QRX003 for Netherton Syndrome in Dermatology and Therapy
Globe Newswire•20/10/2026•06:30 ET
0
Key Highlights
- ➤QRX003 pediatric case achieved clear skin and zero itch by eight months
- ➤QRX003 patient remained mostly clear and itch-free through 21 months
- ➤Phase 2/3 interim results: four of six participants met primary endpoint
- ➤Quoin expects full Phase 2/3 enrollment by end-2026, topline data Q2 2027
Expert Statements
Alan Irvine, Consultant dermatologist at Children’s Health Ireland and professor of dermatology at Trinity College Dublin
“The authors note that these single-patient observations are consistent with a possible treatment-associated effect, and that ongoing clinical trials will further evaluate the safety and efficacy of QRX003.”
Michael Myers, Chief Executive Officer and Co-Founder of Quoin Pharmaceuticals
“Publication of this paper makes the scientific rationale behind QRX003, and Professor Irvine’s clinical experience with it, available to the broader dermatology and Netherton communities. Netherton Syndrome remains unfamiliar to many physicians, and peer-reviewed evidence such as this plays an important role in building awareness of the disease and of new approaches to treating it.”
Michael Myers, Chief Executive Officer and Co-Founder of Quoin Pharmaceuticals
“We are grateful to the patient and family for allowing this experience to be shared. This case report adds to a growing body of clinical evidence for QRX003, from our pediatric compassionate use program to the positive interim results from our ongoing Phase 2/3 study. We look forward to completing recruitment in that study by the end of this year.”
– Peer-Reviewed Paper Introducing QRX003 and Its Mechanism of Action in Netherton Syndrome Now Published
– Case Report Details 21 Months of Compassionate Use Treatment in a Pediatric Patient
Get started
Create a free account to read the full story.